The year started strong for Jazz Pharmaceuticals (JAZZ) with a Q4 2024 revenue beat and the company guiding 2025 revenues just slightly below the analyst consensus. However, the stock is down 22% ...
Last year was marked by significant change within the federal government. Much was jettisoned: notably, foreign aid, along with huge swaths of the Centers for Disease Control and Prevention and the ...
Of all the abductions, this one is different.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results